AskBio has acquired Synpromics, a provider of gene control synthetic promoter technology, bioinformatics, and intelligent data-driven design, to enable more precise cell targeting and gene expression. Synpromics will operate as a wholly owned subsidiary and remain headquartered in Edinburgh, UK.   AskBio’s AAV technology and multi-dimensional gene therapy platform combined with Synpromics’ promoter and bioinformatics technology create an opportunity to more accurately target complex diseases and...